55 related articles for article (PubMed ID: 34824020)
1. Clinical and molecular characteristics and risk factors for patients acquiring carbapenemase-producing and non-carbapenemase-producing carbapenem-nonsusceptible-Enterobacterales bacteremia.
Wu AY; Chang H; Wang NY; Sun FJ; Liu CP
J Microbiol Immunol Infect; 2022 Dec; 55(6 Pt 2):1229-1238. PubMed ID: 34824020
[TBL] [Abstract][Full Text] [Related]
2. Systematic Analysis of Mobile Genetic Elements Mediating β-Lactamase Gene Amplification in Noncarbapenemase-Producing Carbapenem-Resistant
Shropshire WC; Konovalova A; McDaneld P; Gohel M; Strope B; Sahasrabhojane P; Tran CN; Greenberg D; Kim J; Zhan X; Aitken S; Bhatti M; Savidge TC; Treangen TJ; Hanson BM; Arias CA; Shelburne SA
mSystems; 2022 Oct; 7(5):e0047622. PubMed ID: 36036505
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and characteristics of ertapenem-mono-resistant isolates among carbapenem-resistant Enterobacterales in China.
Wang Y; Hu H; Shi Q; Zhang P; Zhao D; Jiang Y; Yu Y
Emerg Microbes Infect; 2024 Dec; 13(1):2332658. PubMed ID: 38517707
[TBL] [Abstract][Full Text] [Related]
4. Carbapenem-Resistant and Extended-Spectrum β-Lactamase-Producing Enterobacterales in Children, United States, 2016-2020.
Grome HN; Grass JE; Duffy N; Bulens SN; Ansari U; Campbell D; Lutgring JD; Gargis AS; Masters T; Kent AG; McKay SL; Smith G; Wilson LE; Vaeth E; Evenson B; Dumyati G; Tsay R; Phipps E; Flores K; Wilson CD; Czaja CA; Johnston H; Janelle SJ; Lynfield R; O'Malley S; Vagnone PS; Maloney M; Nadle J; Guh AY
Emerg Infect Dis; 2024 Jun; 30(6):1104-1114. PubMed ID: 38781979
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the BD Phoenix CPO Detect Test for the detection of carbapenemase-producing Enterobacterales.
Ozyurt OK; Cetinkaya O; Ozhak B; Ongut G; Turhan O; Yazisiz H; Donmez L; Kuskucu MA; Midilli K; Ogunc D
Future Microbiol; 2023 May; 18():399-405. PubMed ID: 37256285
[TBL] [Abstract][Full Text] [Related]
6. IS26-mediated amplification of blaOXA-1 and blaCTX-M-15 with concurrent outer membrane porin disruption associated with de novo carbapenem resistance in a recurrent bacteraemia cohort.
Shropshire WC; Aitken SL; Pifer R; Kim J; Bhatti MM; Li X; Kalia A; Galloway-Peña J; Sahasrabhojane P; Arias CA; Greenberg DE; Hanson BM; Shelburne SA
J Antimicrob Chemother; 2021 Jan; 76(2):385-395. PubMed ID: 33164081
[TBL] [Abstract][Full Text] [Related]
7. International Epidemiology of Carbapenemase-Producing Escherichia coli.
Boutzoukas AE; Komarow L; Chen L; Hanson B; Kanj SS; Liu Z; Salcedo Mendoza S; Ordoñez K; Wang M; Paterson DL; Evans S; Ge L; Giri A; Hill C; Baum K; Bonomo RA; Kreiswirth B; Patel R; Arias CA; Chambers HF; Fowler VG; van Duin D;
Clin Infect Dis; 2023 Aug; 77(4):499-509. PubMed ID: 37154071
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the French novel disc diffusion-based algorithm and the current EUCAST guidelines for the screening of carbapenemase-producing Enterobacterales.
Duque M; Bonnin RA; Dortet L
J Antimicrob Chemother; 2024 May; 79(5):1194-1196. PubMed ID: 38412338
[No Abstract] [Full Text] [Related]
9. Factors associated with non-carbapenemase mediated carbapenem resistance of Gram-negative bacteria: a retrospective case-control study.
Müller M; Wiencierz A; Gehringer C; Muigg V; Bassetti S; Siegemund M; Hinic V; Tschudin-Sutter S; Egli A
Int Microbiol; 2024 Apr; 27(2):597-606. PubMed ID: 37556067
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology and antimicrobial susceptibility profiles of Enterobacterales causing bloodstream infections before and during COVID-19 pandemic: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART) in Taiwan, 2018-2021.
Lee YL; Liu CE; Tang HJ; Huang YT; Chen YS; Hsueh PR;
J Microbiol Immunol Infect; 2024 Apr; ():. PubMed ID: 38632023
[TBL] [Abstract][Full Text] [Related]
11. Identifying Effective Durations of Antibiotic Therapy for the Treatment of Carbapenem-resistant Enterobacterales Bloodstream Infections: A Multicenter Observational Study.
Soto CL; Hsu AJ; Lee JH; Dzintars K; Choudhury R; Jenkins TC; McCreary EK; Quartuccio KS; Stohs EJ; Zimmerman M; Tamma PD
Clin Infect Dis; 2024 Jan; 78(1):27-30. PubMed ID: 37584360
[TBL] [Abstract][Full Text] [Related]
12. A practical approach to screening for carbapenemase-producing Enterobacterales- views of a group of multidisciplinary experts from English hospitals.
Jenkins DR; Auckland C; Chadwick C; Dodgson AR; Enoch DA; Goldenberg SD; Hussain A; Martin J; Spooner E; Whalley T
BMC Infect Dis; 2024 Apr; 24(1):444. PubMed ID: 38671365
[TBL] [Abstract][Full Text] [Related]
13. Dissemination of carbapenemase-producing Enterobacteriaceae and associated resistance determinants through global food systems.
Harding-Crooks R; Smith D; Fanning S; Fox EM
Compr Rev Food Sci Food Saf; 2023 Jul; 22(4):2706-2727. PubMed ID: 37083194
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial Use and Carbapenem-Resistant Enterobacterales in Korea: A Nationwide Case-Control Study With Propensity Score Matching.
Kwon KT; Kim Y; Kim SW; Chang HH; Hwang S; Bae S; Nam E
J Korean Med Sci; 2024 Apr; 39(14):e132. PubMed ID: 38622938
[TBL] [Abstract][Full Text] [Related]
15. Customized molecular diagnostics of bacterial bloodstream infections for carbapenem resistance: A convenient and affordable approach.
Mallick A; Roy A; Sarkar S; Mondal KC; Das S
Pathog Glob Health; 2023 Oct; 117(7):631-638. PubMed ID: 37069793
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization of Carbapenem resistant Enterobacterales causing blood stream infections in critically ill patients.
Gupta S; Rajni E; Galav H; Gajjar D
Indian J Med Microbiol; 2024; 47():100484. PubMed ID: 37871383
[No Abstract] [Full Text] [Related]
17. Using the CLSI rAST breakpoints of Enterobacterales in positive blood cultures.
Deng J; An Y; Kang M
Diagn Microbiol Infect Dis; 2024 Jul; 109(3):116335. PubMed ID: 38703531
[TBL] [Abstract][Full Text] [Related]
18. Epidemiological and clinical characterization of community, healthcare-associated and nosocomial colonization and infection due to carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in Spain.
Salamanca-Rivera E; Palacios-Baena ZR; Cañada JE; Moure Z; Pérez-Vázquez M; Calvo-Montes J; Martínez-Martínez L; Cantón R; Ruiz Carrascoso G; Pitart C; Navarro F; Bou G; Mulet X; González-López JJ; Sivianes F; Delgado-Valverde M; Pascual Á; Oteo-Iglesias J; Rodríguez-Baño J;
Infection; 2024 May; ():. PubMed ID: 38703288
[TBL] [Abstract][Full Text] [Related]
19. Carbapenem use in extended-spectrum cephalosporin-resistant Enterobacterales infections in US hospitals and influence of IDSA guidance: a retrospective cohort study.
Walker MK; Diao G; Warner S; Babiker A; Neupane M; Strich JR; Yek C; Kadri SS;
Lancet Infect Dis; 2024 Apr; ():. PubMed ID: 38679036
[TBL] [Abstract][Full Text] [Related]
20. Contributing Factors to the Clinical and Economic Burden of Patients with Laboratory-Confirmed Carbapenem-Nonsusceptible Gram-Negative Respiratory Infections.
McCann E; Sung AH; Ye G; Vankeepuram L; Tabak YP
Infect Drug Resist; 2020; 13():761-771. PubMed ID: 32210590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
